Display options
Cite
Wang A. Efficacy of class III antiarrhythmics and magnesium combination therapy for atrial fibrillation. Pharm Pract (Granada). 2012;10(2):65-71doi: 10.4321/s1886-36552012000200001.
Wang, A. (2012). Efficacy of class III antiarrhythmics and magnesium combination therapy for atrial fibrillation. Pharmacy practice, 10(2), 65-71. https://doi.org/10.4321/s1886-36552012000200001
Wang, Amy. "Efficacy of class III antiarrhythmics and magnesium combination therapy for atrial fibrillation." Pharmacy practice vol. 10,2 (2012): 65-71. doi: https://doi.org/10.4321/s1886-36552012000200001
Wang A. Efficacy of class III antiarrhythmics and magnesium combination therapy for atrial fibrillation. Pharm Pract (Granada). 2012 Apr;10(2):65-71. doi: 10.4321/s1886-36552012000200001. Epub 2012 Jun 30. PMID: 24155819; PMCID: PMC3780486.
Copy Download .nbib Format: NLM
Share it on

Pharm Pract (Granada). 2012 Apr;10(2):65-71. doi: 10.4321/s1886-36552012000200001. Epub 2012 Jun 30.

Efficacy of class III antiarrhythmics and magnesium combination therapy for atrial fibrillation.

Pharmacy practice

Amy Wang

Affiliations

  1. Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University . Brooklyn, NY ( United States ).

PMID: 24155819 PMCID: PMC3780486 DOI: 10.4321/s1886-36552012000200001

Abstract

UNLABELLED: Atrial fibrillation is a common cardiac arrhythmia, and has been a significant financial burden. Class III antiarrhythmics such as dofetilide, ibutilide, and amiodarone are indicated for rhythm control. Magnesium may possess intrinsic antiarrhythmic properties, and may potentially increase the efficacy of class III antiarrhythmics when used concomitantly.

OBJECTIVE: The purpose of this article is to review the literature on the efficacy of magnesium in addition to Class III antiarrhythmics, specifically amidarone, ibutilide, and dofetilide for the cardioversion of atrial fibrillation.

METHODS: Databases Pubmed and CINAHL are utilized along with the search terms amiodarone, dofetilide, ibutlide, magnesium, atrial fibrillation, conversion, rhythm control, and cardioversion.

RESULTS: One study on dofetilide and 5 studies on ibutilide were identified. No studies were found on amiodarone. Patients with atrial fibrillation who received dofetilide and magnesium had higher rates of successful cardioversion as compared to those who only received dofetilide. Conversion rates were similar between the 2 treatment groups for patients with atrial flutter. As for ibutilide, 4 studies have shown that the addition of magnesium significantly increases conversion rates for patients with atrial fibrillation or typical atrial flutter. Conversion rates were similar for patients with atypical atrial flutter. One study showed that addition of magnesium did not improve efficacy of ibutilide. Higher doses of magnesium (4 g) were associated with improved outcomes. Adverse effects of magnesium were mild and included flushing, tingling, and dizziness. Patients who received magnesium had shorter corrected QT intervals and smaller increase in corrected QT interval from baseline. Compare to previous studies, studies included in this review had higher conversion rates for dofetilide and ibutilide as well as dofetilide and magnesium or ibutilide and magnesium combination therapies. However, only 2 ibutilide studies and 1 dofetilide study reported baseline characteristics such as left atrial size, history of heart failure, and duration of atrial fibrillation, which are significant predictors of successful cardioversion. Therefore, differences in baseline demographics may have influenced the results.

CONCLUSIONS: Magnesium may be used as adjunct for dofetilide and ibutilide due to potential improved efficacy and minimal toxicity. Dose ranging studies should be conducted in the future to establish the optimal dose and duration of therapy as well as the optimal serum magnesium concentration in order for the clinician to manage and monitor patients appropriately.

Keywords: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Magnesium Sulfate

References

  1. Int J Cardiol. 2003 Jun;89(2-3):239-48 - PubMed
  2. Heart. 2007 Nov;93(11):1433-40 - PubMed
  3. Aust Crit Care. 2003 Nov;16(4):144-9 - PubMed
  4. Am Heart J. 1991 May;121(5):1513-21 - PubMed
  5. J Am Coll Cardiol. 2010 Mar 2;55(9):934-47 - PubMed
  6. J Am Coll Cardiol. 2006 Aug 15;48(4):854-906 - PubMed
  7. Clin Cardiol. 1989 Feb;12(2):85-90 - PubMed
  8. Biochem Pharmacol. 1989 Mar 15;38(6):859-67 - PubMed
  9. Europace. 2009 Jul;11(7):892-5 - PubMed
  10. J Am Coll Cardiol. 2011 Jan 11;57(2):223-42 - PubMed
  11. J Am Coll Cardiol. 1996 Apr;27(5):1079-82 - PubMed
  12. Pharmacotherapy. 1999 May;19(5):635-40 - PubMed
  13. Clin Cardiol. 1993 May;16(5):429-34 - PubMed
  14. Am J Cardiol. 2010 Sep 1;106(5):673-6 - PubMed
  15. Am J Health Syst Pharm. 2003 Nov 15;60(22):2308-12 - PubMed
  16. Pharmacotherapy. 2003 Mar;23(3):296-300 - PubMed
  17. Am Heart J. 1998 Oct;136(4 Pt 1):632-42 - PubMed
  18. Am J Health Syst Pharm. 1998 Feb 1;55(3):255-60 - PubMed
  19. Int J Cardiol. 2010 Jun 11;141(3):260-5 - PubMed
  20. Pacing Clin Electrophysiol. 2007 Nov;30(11):1331-5 - PubMed
  21. Circulation. 1996 Oct 1;94(7):1613-21 - PubMed
  22. Circulation. 2000 Nov 7;102(19):2385-90 - PubMed
  23. Am J Cardiol. 2003 Mar 20;91(6A):39D-44D - PubMed
  24. Am J Cardiol. 2007 Jun 15;99(12):1726-32 - PubMed
  25. N Engl J Med. 1999 Sep 16;341(12):857-65 - PubMed

Publication Types